Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $32000.0.

  • Utah Medical Products' Change in Account Payables fell 8036.81% to $32000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$233000.0, marking a year-over-year decrease of 14804.12%. This contributed to the annual value of -$73000.0 for FY2024, which is 8399.12% up from last year.
  • Utah Medical Products' Change in Account Payables amounted to $32000.0 in Q3 2025, which was down 8036.81% from -$180000.0 recorded in Q2 2025.
  • Utah Medical Products' Change in Account Payables' 5-year high stood at $695000.0 during Q1 2022, with a 5-year trough of -$826000.0 in Q3 2023.
  • Over the past 5 years, Utah Medical Products' median Change in Account Payables value was $32000.0 (recorded in 2025), while the average stood at -$1000.0.
  • As far as peak fluctuations go, Utah Medical Products' Change in Account Payables plummeted by 30229.01% in 2021, and later surged by 126274.51% in 2022.
  • Utah Medical Products' Change in Account Payables (Quarter) stood at -$265000.0 in 2021, then surged by 71.32% to -$76000.0 in 2022, then soared by 436.84% to $256000.0 in 2023, then tumbled by 217.97% to -$302000.0 in 2024, then soared by 110.6% to $32000.0 in 2025.
  • Its last three reported values are $32000.0 in Q3 2025, -$180000.0 for Q2 2025, and $217000.0 during Q1 2025.